245 results on '"Miyauchi, Eisaku"'
Search Results
2. Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial
3. Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1–49 %): TOPGAN2023-01
4. Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility
5. Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
6. Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
7. The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non–small cell lung cancer: A multicenter retrospective cohort study
8. Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice
9. Urine autotaxin levels reflect the disease activity of sarcoidosis
10. Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC
11. Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)
12. Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: A multi-center retrospective study
13. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512)
14. 11β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma
15. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer.
16. MO10-2 Clinical decisions by the Molecular Tumor Board on comprehensive genomic profiling tests in Japan: A retrospective observational study
17. MO57-5 Multicenter retrospective study to evaluate necitumumab plus CDDP/GEM after ICIs in advanced squamous-cell lung cancer in Japan (NINJA study)
18. MO56-2 Efficacy of whole brain radiotherapy for patients with leptomeningeal metastasis of non-small cell lung cancer: NEJ049
19. Targeting ErbB and tankyrase1/2 prevent the emergence of drug tolerant persister cells in ALK fusion positive lung cancer
20. Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
21. Phase II trial of daily S‐1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101
22. A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202
23. Pathological images machine learning and prediction of long-term efficacy for immunotherapy in small cell lung cancer.
24. Table S3 from CD45+CD326+ Cells are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients
25. Data from CD45+CD326+ Cells are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients
26. Figure S1 from CD45+CD326+ Cells are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients
27. Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
28. Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer
29. Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment
30. A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
31. Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study
32. Stereotactic Radiosurgery for Lung Cancer with a Risk-Adapted Strategy Using the Volumetric Modulated Arc Therapy Technique: A Single Arm Phase II Study
33. Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study
34. Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.
35. Histologic transformation of epidermal growth factor receptor–mutated lung cancer
36. Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis ( TOPGAN2020 ‐02)
37. Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
38. O3-2-1 - Updated survival outcomes of NEJ005/TCOG0902, a randomized PII of gefitinib and chemotherapy in EGFR-mutant NSCLC
39. Phase I/II study of biweekly nab‐paclitaxel in patients with platinum‐pretreated non‐small cell lung cancer: NJLCG1402
40. Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer—data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
41. Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated .
42. Phase II study of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan Lung Cancer Group 1101 (NJLCG1101)
43. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
44. Targeting stanniocalcin‐1‐expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer
45. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
46. Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01)
47. Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy
48. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512)
49. The clinical significance of plasma and urine lysophospholipids-producing enzymes in patients with sarcoidosis
50. Abstract 3102: Analysis of plasma and serum as a source of circulating tumor DNA for hotspot mutations detection in liquid biopsy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.